Celldex Therapeutics, Inc. (CLDX) - Stock Analysis
Last updated: Apr 4, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Minimal revenue ⢠High cash burn CLDX has strong liquidity and low leverage but negligible revenue, heavy R&D-driven losses, and large negative cash flow that severely impair profitability and distort valuation.
Price Behavior
Key Price Behavior Insights: ⢠Price above SMA ⢠Resistance congestion ⢠Defined support zone Support Level: $29.3â$29.5 Resistance Level: $31.7â$31.8 CLDX is in a short-term uptrendâprice closed above the last month SMA after a recovery from the $24.84 low, but faces clear resistance at $31.7â31.8 and would weaken if $29.3â29.5 support breaks while RSI (~54) is neutral.
Sentiment & News
Key News Insights: ⢠Positive trial readout ⢠~$300M offering ⢠Moderate analyst buy-in Celldex reported strong Phase 2 urticaria data and promptly priced a ~$300M follow-on offering, highlighting simultaneous clinical progress and near-term dilution risk.
AI Summary
CLDX has moved from a cashâsurvival story to a lateâstage, launchâfocused companyâits recent $300M offering materially reduces nearâterm financing risk but makes the investment thesis hinge on barzolvolimab's pivotal readouts and flawless early commercialization/payer execution. Monitor the timing/outcome of the Phase 3 readouts and initial payer/pricing signals closelyâpositive results plus early favorable access would justify upside, while any clinical setbacks, launch execution gaps, or higherâthanâexpected commercial burn will likely trigger sharp downside.
Description
Celldex Therapeutics is a biopharmaceutical company developing monoclonal and bispecific antibody therapies for inflammatory conditions and various cancers. Its clinical pipeline includes programs directed at KIT, CD40 and a bispecific combining PD-L1 blockade with CD27 costimulation, among other antibody candidates. The company maintains research and licensing relationships with academic institutions and Amgen, and is headquartered in Hampton, New Jersey, having been incorporated in 1983.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 26 | Mar 5 | CLDX | Celldex Therapeutics, Inc. | Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade. | Closed | -4.2% |